Fulcrum Therapeutics Signs an Exclusive Worldwide License Agreement with GSK to Develop and Commercialize Losmapimod for Facioscapulohumeral Muscular Dystrophy

Fulcrum Therapeutics Signs an Exclusive Worldwide License Agreement with GSK to Develop and Commercialize Losmapimod for Facioscapulohumeral Muscular Dystrophy

Shots:

  • GSK to receive shares of Fulcrum’s preferred stock, milestones & royalties on sales of losmapimod. Fulcrum to get exclusive WW rights to develop & commercialize of losmapimod with all patent rights
  • Fulcrum has conducted pre-clinical testing of losmapimod and identified it as potent regulator of DUX4 gene. In mid-2019, Fulcrum plans for the onset of P-IIb trial of losmapimod in patients with FSHD across multiple sites in the US and Europe
  • Losmapimod is a selective p38α/β mitogen activated protein kinase (MAPK) inhibitor, evaluated in 3,500 candidates for multiple indication in 24 clinical studies

Click here to read full press release/ article | Ref: Fulcrum Therapeutics | Image: MT2G